Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Cancer Patients 1Pancreatic Neoplasms 1Locally Advanced Rectal Cancer 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 47Carboplatin 36Paclitaxel 29Specimen Handling 19Cyclophosphamide 18Capecitabine 16Magnetic Resonance Spectroscopy 15sacituzumab govitecan 13Taxes 13Gemcitabine 13Biopsy 12130-nm albumin-bound paclitaxel 11Doxorubicin 9Albumin-Bound Paclitaxel 9olaparib 8Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Immunoglobulin G 4Fulvestrant 4Epirubicin 4Drug Therapy 4Bevacizumab 4veliparib 3toripalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × camrelizumab × 90 days × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Fudan University

Phase 2 Recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Harbin Medical University

Phase 2 Active not recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡